Immuron Dividends and Buybacks
Dividend criteria checks 0/6
Immuron does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-0.1%
Buyback Yield
| Total Shareholder Yield | -0.1% |
| Future Dividend Yield | n/a |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Immuron suspends research on COVID-19 program
Aug 19Immuron says proposed trials of antibacterial drug put on clinical hold by FDA
Jul 26Immuron to get European patent for drug composition to treat bacterial infection
Jul 07Immuron inks SARS-CoV-2 research agreement with Monash University, shares +12%
Dec 15Immuron soars 26% on positive vaccine responses in gut mediated pathogens
Nov 11Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if IMRN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IMRN's dividend payments have been increasing.
Dividend Yield vs Market
| Immuron Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (IMRN) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.2% |
| Industry Average (Biotechs) | 2.3% |
| Analyst forecast (IMRN) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate IMRN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IMRN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate IMRN's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as IMRN has not reported any payouts.